Trade ADMA Biologics, Inc. - ADMA CFD
Add to favourite- Summary
- Historical Data
- Events
- Income Statement
- Balance Sheet
- Cash Flow
Trading сonditions
| Spread | 0.0314 | ||||||||
|
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
|
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
*Information provided by Capital.com
ADMA Biologics Inc ESG Risk Ratings
High Medium Low Negligible
‘D’ score indicates poor relative ESG performance and insufficient degree of transparency in reporting material ESG data publicly.
Key Stats
| Prev. Close* | 5.9593 |
| Open* | 5.9293 |
| 1-Year Change* | 87.03% |
| Day's Range* | 5.9293 - 6.2193 |
| 52 wk Range | 2.95-5.10 |
| Average Volume (10 days) | 3.31M |
| Average Volume (3 months) | 42.78M |
| Market Cap | 1.13B |
| P/E Ratio | -100.00K |
| Shares Outstanding | 225.97M |
| Revenue | 234.29M |
| EPS | -0.11 |
| Dividend (Yield %) | N/A |
| Beta | 0.46 |
| Next Earnings Date | Mar 21, 2024 |
All data is provided by Refinitiv, except for data marked with an asterisk, which is *data provided by Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 15, 2024 | 5.9593 | -0.0100 | -0.17% | 5.9693 | 6.1893 | 5.9193 |
| Apr 12, 2024 | 5.9993 | -0.1900 | -3.07% | 6.1893 | 6.1993 | 5.9593 |
| Apr 11, 2024 | 6.1993 | 0.1500 | 2.48% | 6.0493 | 6.2093 | 6.0393 |
| Apr 10, 2024 | 6.0193 | 0.0500 | 0.84% | 5.9693 | 6.0593 | 5.8793 |
| Apr 9, 2024 | 6.0893 | -0.0700 | -1.14% | 6.1593 | 6.2393 | 6.0393 |
| Apr 8, 2024 | 6.1893 | -0.1700 | -2.67% | 6.3593 | 6.3793 | 6.1493 |
| Apr 5, 2024 | 6.3693 | 0.1300 | 2.08% | 6.2393 | 6.4693 | 6.1893 |
| Apr 4, 2024 | 6.2693 | -0.1200 | -1.88% | 6.3893 | 6.4293 | 6.2593 |
| Apr 3, 2024 | 6.3193 | -0.0900 | -1.40% | 6.4093 | 6.4393 | 6.2793 |
| Apr 2, 2024 | 6.4193 | -0.0400 | -0.62% | 6.4593 | 6.4893 | 6.3493 |
| Apr 1, 2024 | 6.5193 | -0.0900 | -1.36% | 6.6093 | 6.6393 | 6.4593 |
| Mar 28, 2024 | 6.5793 | -0.1200 | -1.79% | 6.6993 | 6.7293 | 6.4993 |
| Mar 27, 2024 | 6.7293 | 0.1800 | 2.75% | 6.5493 | 6.7293 | 6.4793 |
| Mar 26, 2024 | 6.4793 | 0.0100 | 0.15% | 6.4693 | 6.5993 | 6.4693 |
| Mar 25, 2024 | 6.3793 | 0.0900 | 1.43% | 6.2893 | 6.4893 | 6.2693 |
| Mar 22, 2024 | 6.2793 | 0.0300 | 0.48% | 6.2493 | 6.4493 | 6.2193 |
| Mar 21, 2024 | 6.1793 | -0.0900 | -1.44% | 6.2693 | 6.4193 | 6.1393 |
| Mar 20, 2024 | 6.3093 | 0.1700 | 2.77% | 6.1393 | 6.3093 | 6.0793 |
| Mar 19, 2024 | 6.1693 | 0.2600 | 4.40% | 5.9093 | 6.1693 | 5.8693 |
| Mar 18, 2024 | 5.9293 | -0.0800 | -1.33% | 6.0093 | 6.0193 | 5.9093 |
ADMA Biologics, Inc. Events
| Time (UTC) | Country | Event |
|---|---|---|
| Wednesday, May 8, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q1 2024 ADMA Biologics Inc Earnings Release Q1 2024 ADMA Biologics Inc Earnings ReleaseForecast -Previous - |
| Wednesday, June 5, 2024 | ||
| Time (UTC) 14:00 | Country US
| Event ADMA Biologics Inc Annual Shareholders Meeting ADMA Biologics Inc Annual Shareholders MeetingForecast -Previous - |
| Wednesday, August 7, 2024 | ||
| Time (UTC) 10:59 | Country US
| Event Q2 2024 ADMA Biologics Inc Earnings Release Q2 2024 ADMA Biologics Inc Earnings ReleaseForecast -Previous - |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total revenue | 154.08 | 80.9426 | 42.2198 | 29.3491 | 16.9853 |
| Revenue | 154.08 | 80.9426 | 42.2198 | 29.3491 | 16.9853 |
| Cost of Revenue, Total | 118.815 | 79.7693 | 61.2914 | 39.5042 | 42.1946 |
| Gross Profit | 35.2651 | 1.17329 | -19.0716 | -10.1552 | -25.2094 |
| Total Operating Expense | 200.115 | 139.316 | 106.143 | 80.7359 | 77.2742 |
| Selling/General/Admin. Expenses, Total | 70.3011 | 55.1856 | 39.2209 | 28.0804 | 30.3085 |
| Research & Development | 3.61376 | 3.64606 | 5.90701 | 2.34385 | 3.92612 |
| Unusual Expense (Income) | 6.66994 | 0 | -0.9918 | 9.9625 | 0 |
| Operating Income | -46.035 | -58.3737 | -63.9231 | -51.3868 | -60.2889 |
| Interest Income (Expense), Net Non-Operating | -19.2345 | -13.0223 | -11.6969 | -8.19259 | -5.32738 |
| Other, Net | -0.63439 | -0.25158 | -0.12853 | -0.22732 | -0.12712 |
| Net Income Before Taxes | -65.904 | -71.6476 | -75.7486 | -48.2793 | -65.7434 |
| Net Income After Taxes | -65.904 | -71.6476 | -75.7486 | -48.2793 | -65.7434 |
| Net Income Before Extra. Items | -65.904 | -71.6476 | -75.7486 | -48.2793 | -65.7434 |
| Net Income | -65.904 | -71.6476 | -75.7486 | -48.2793 | -65.7434 |
| Income Available to Common Excl. Extra. Items | -65.904 | -71.6476 | -75.7486 | -48.2793 | -65.7434 |
| Income Available to Common Incl. Extra. Items | -65.904 | -71.6476 | -75.7486 | -48.2793 | -65.7434 |
| Diluted Net Income | -65.904 | -71.6476 | -75.7486 | -48.2793 | -65.7434 |
| Diluted Weighted Average Shares | 197.875 | 139.579 | 86.1451 | 54.3481 | 45.1889 |
| Diluted EPS Excluding Extraordinary Items | -0.33306 | -0.51331 | -0.87931 | -0.88833 | -1.45486 |
| Diluted Normalized EPS | -0.29935 | -0.51331 | -0.89083 | -0.91713 | -1.45486 |
| Depreciation / Amortization | 0.71535 | 0.71535 | 0.71535 | 0.84494 | 0.84494 |
| Total Extraordinary Items | |||||
| Gain (Loss) on Sale of Assets | 0 | 11.5274 |
| Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | |
|---|---|---|---|---|---|
| Total revenue | 60.1232 | 56.9135 | 49.9815 | 41.0901 | 33.905 |
| Revenue | 60.1232 | 56.9135 | 49.9815 | 41.0901 | 33.905 |
| Cost of Revenue, Total | 43.4332 | 40.4005 | 35.8044 | 31.4335 | 26.1356 |
| Gross Profit | 16.69 | 16.513 | 14.1771 | 9.65664 | 7.7694 |
| Total Operating Expense | 60.5963 | 57.7268 | 56.04 | 50.4069 | 43.0798 |
| Selling/General/Admin. Expenses, Total | 15.581 | 16.2921 | 18.9825 | 17.7526 | 15.8919 |
| Research & Development | 1.40326 | 0.85535 | 1.07432 | 1.04195 | 0.87339 |
| Depreciation / Amortization | 0.17884 | 0.17884 | 0.17884 | 0.17884 | 0.17884 |
| Operating Income | -0.47308 | -0.81332 | -6.05854 | -9.31673 | -9.17474 |
| Interest Income (Expense), Net Non-Operating | -5.88481 | -5.94851 | -5.73469 | -5.57313 | -4.57075 |
| Other, Net | -0.01283 | -0.02698 | -0.43845 | -0.00964 | -0.01942 |
| Net Income Before Taxes | -6.37071 | -6.78882 | -12.2317 | -14.8995 | -13.7649 |
| Net Income After Taxes | -6.37071 | -6.78882 | -12.2317 | -14.8995 | -13.7649 |
| Net Income Before Extra. Items | -6.37071 | -6.78882 | -12.2317 | -14.8995 | -13.7649 |
| Net Income | -6.37071 | -6.78882 | -12.2317 | -14.8995 | -13.7649 |
| Income Available to Common Excl. Extra. Items | -6.37071 | -6.78882 | -12.2317 | -14.8995 | -13.7649 |
| Income Available to Common Incl. Extra. Items | -6.37071 | -6.78882 | -12.2317 | -14.8995 | -13.7649 |
| Diluted Net Income | -6.37071 | -6.78882 | -12.2317 | -14.8995 | -13.7649 |
| Diluted Weighted Average Shares | 222.683 | 221.922 | 202.885 | 196.384 | 196.353 |
| Diluted EPS Excluding Extraordinary Items | -0.02861 | -0.03059 | -0.06029 | -0.07587 | -0.0701 |
| Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
| Diluted Normalized EPS | -0.02861 | -0.03059 | -0.06029 | -0.07587 | -0.0701 |
| Unusual Expense (Income) | 0 | 0 | 0 | 0 | 0 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Total Current Assets | 270.402 | 208.729 | 153.741 | 85.8204 | 44.5296 |
| Cash and Short Term Investments | 86.5215 | 51.0891 | 55.9212 | 26.7521 | 22.7549 |
| Cash & Equivalents | 86.5215 | 51.0891 | 55.9212 | 26.7521 | 22.7549 |
| Short Term Investments | |||||
| Total Receivables, Net | 15.505 | 28.5769 | 13.2373 | 3.46992 | 1.39244 |
| Accounts Receivable - Trade, Net | 15.505 | 28.5769 | 13.2373 | 3.46992 | 1.39244 |
| Total Inventory | 163.28 | 124.724 | 81.5356 | 53.0647 | 18.6162 |
| Prepaid Expenses | 5.09515 | 4.33925 | 3.04647 | 2.53359 | 1.76616 |
| Total Assets | 348.462 | 276.253 | 207.673 | 127.091 | 88.8765 |
| Property/Plant/Equipment, Total - Net | 68.7469 | 58.1977 | 45.8523 | 33.1413 | 30.1157 |
| Property/Plant/Equipment, Total - Gross | 88.2235 | 71.4696 | 54.7162 | 38.8663 | 33.5368 |
| Accumulated Depreciation, Total | -19.4765 | -13.2718 | -8.86394 | -5.72496 | -3.42103 |
| Other Long Term Assets, Total | 4.77025 | 4.0674 | 2.10698 | 1.44004 | 6.69725 |
| Total Current Liabilities | 39.2669 | 30.3783 | 19.9474 | 14.0279 | 9.62505 |
| Accounts Payable | 13.2294 | 12.4294 | 11.0737 | 9.17459 | 5.90039 |
| Accrued Expenses | 24.0989 | 16.7941 | 8.73083 | 4.71047 | 3.58182 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Current Port. of LT Debt/Capital Leases | |||||
| Other Current Liabilities, Total | 1.93864 | 1.15482 | 0.14283 | 0.14283 | 0.14283 |
| Total Liabilities | 196.488 | 135.08 | 119.424 | 100.898 | 69.1061 |
| Total Long Term Debt | 142.833 | 94.8662 | 92.9689 | 83.1992 | 44.075 |
| Long Term Debt | 142.833 | 94.8662 | 92.9689 | 83.1992 | 44.075 |
| Other Liabilities, Total | 14.3877 | 9.8356 | 6.50774 | 3.67047 | 15.406 |
| Total Equity | 151.974 | 141.173 | 88.2494 | 26.1931 | 19.7704 |
| Common Stock | 0.02218 | 0.01958 | 0.01049 | 0.00593 | 0.00464 |
| Additional Paid-In Capital | 629.969 | 553.266 | 428.704 | 290.904 | 236.203 |
| Retained Earnings (Accumulated Deficit) | -478.017 | -412.113 | -340.465 | -264.717 | -216.437 |
| Total Liabilities & Shareholders’ Equity | 348.462 | 276.253 | 207.673 | 127.091 | 88.8765 |
| Total Common Shares Outstanding | 221.817 | 195.814 | 104.903 | 59.3184 | 46.3531 |
| Other Current Assets, Total | 0 | ||||
| Goodwill, Net | 3.52951 | 3.52951 | 3.52951 | 3.52951 | 3.52951 |
| Intangibles, Net | 1.01342 | 1.72877 | 2.44412 | 3.15947 | 4.00441 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | Sep 2022 | |
|---|---|---|---|---|---|
| Total Current Assets | 273.699 | 266.243 | 264.086 | 270.402 | 224.095 |
| Cash and Short Term Investments | 74.1568 | 62.5129 | 69.2042 | 86.5215 | 34.906 |
| Cash & Equivalents | 74.1568 | 62.5129 | 69.2042 | 86.5215 | 34.906 |
| Total Receivables, Net | 31.3187 | 36.7316 | 26.5185 | 15.505 | 20.9024 |
| Accounts Receivable - Trade, Net | 31.3187 | 36.7316 | 26.5185 | 15.505 | 20.9024 |
| Total Inventory | 163.116 | 161.78 | 163.985 | 163.28 | 162.914 |
| Prepaid Expenses | 5.10746 | 5.21874 | 4.37868 | 5.09515 | 5.37248 |
| Total Assets | 348.997 | 343.027 | 340.788 | 348.462 | 300.558 |
| Property/Plant/Equipment, Total - Net | 64.5683 | 66.3094 | 67.6185 | 68.7469 | 67.282 |
| Property/Plant/Equipment, Total - Gross | 89.6843 | 89.5134 | 88.9036 | 88.2235 | 85.1784 |
| Accumulated Depreciation, Total | -25.116 | -23.2039 | -21.2852 | -19.4765 | -17.8964 |
| Goodwill, Net | 3.52951 | 3.52951 | 3.52951 | 3.52951 | 3.52951 |
| Intangibles, Net | 0.4769 | 0.65574 | 0.83458 | 1.01342 | 1.19225 |
| Other Long Term Assets, Total | 6.72282 | 6.28905 | 4.71876 | 4.77025 | 4.45932 |
| Total Current Liabilities | 41.8409 | 41.9525 | 36.7278 | 39.2669 | 44.4403 |
| Accounts Payable | 10.8514 | 12.0845 | 12.9565 | 13.2294 | 25.1978 |
| Accrued Expenses | 28.2332 | 27.5276 | 21.5867 | 24.0989 | 16.994 |
| Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities, Total | 2.75622 | 2.34033 | 2.18469 | 1.93864 | 2.24849 |
| Total Liabilities | 197.559 | 196.265 | 195.133 | 196.488 | 200.173 |
| Total Long Term Debt | 142.026 | 140.312 | 144.301 | 142.833 | 141.366 |
| Long Term Debt | 142.026 | 140.312 | 144.301 | 142.833 | 141.366 |
| Other Liabilities, Total | 13.6928 | 14.0002 | 14.1042 | 14.3877 | 14.367 |
| Total Equity | 151.437 | 146.762 | 145.655 | 151.974 | 100.385 |
| Preferred Stock - Non Redeemable, Net | 0 | 0 | 0 | 0 | 0 |
| Common Stock | 0.0226 | 0.02245 | 0.02223 | 0.02218 | 0.01968 |
| Additional Paid-In Capital | 640.026 | 637.916 | 630.438 | 629.969 | 566.15 |
| Retained Earnings (Accumulated Deficit) | -488.611 | -491.176 | -484.805 | -478.017 | -465.785 |
| Total Liabilities & Shareholders’ Equity | 348.997 | 343.027 | 340.788 | 348.462 | 300.558 |
| Total Common Shares Outstanding | 225.958 | 224.527 | 222.263 | 221.817 | 196.777 |
- Annual
- Quarterly
| 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -65.904 | -71.6476 | -75.7486 | -48.2793 | -65.7434 |
| Cash From Operating Activities | -59.5083 | -112.369 | -102.003 | -76.1935 | -62.6787 |
| Cash From Operating Activities | 7.11337 | 5.4955 | 3.94229 | 3.25815 | 3.4464 |
| Non-Cash Items | 17.5676 | 5.46355 | 3.58462 | 2.33044 | 3.30681 |
| Cash Interest Paid | 13.88 | 11.1595 | 10.2676 | 8.11223 | 4.39997 |
| Changes in Working Capital | -18.2853 | -51.6804 | -33.7813 | -33.5028 | -3.68844 |
| Cash From Investing Activities | -13.9112 | -13.5113 | -12.7247 | -3.81184 | -2.0956 |
| Capital Expenditures | -13.9112 | -13.5113 | -12.7267 | -3.81184 | -2.0956 |
| Other Investing Cash Flow Items, Total | 0 | 0.002 | 0 | ||
| Cash From Financing Activities | 108.852 | 121.048 | 143.897 | 80.0026 | 42.9216 |
| Financing Cash Flow Items | -7.68177 | -0.0616 | -0.83 | -10.9395 | 0 |
| Issuance (Retirement) of Stock, Net | 64.8203 | 121.144 | 131.209 | 48.4721 | 42.9578 |
| Issuance (Retirement) of Debt, Net | 51.7133 | -0.0343 | 13.5179 | 42.47 | -0.03628 |
| Net Change in Cash | 35.4324 | -4.83203 | 29.169 | -0.00272 | -21.8527 |
| Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
|---|---|---|---|---|---|
| Net income/Starting Line | -6.78882 | -65.904 | -53.6723 | -38.7728 | -25.0079 |
| Cash From Operating Activities | -14.7223 | -59.5083 | -52.1289 | -38.8442 | -26.0134 |
| Cash From Operating Activities | 2.03297 | 7.11337 | 5.17649 | 3.3145 | 1.59022 |
| Non-Cash Items | 2.56042 | 17.5676 | 14.6492 | 11.4063 | 8.86246 |
| Cash Interest Paid | 4.63928 | 13.88 | 9.61036 | 5.98933 | 2.52599 |
| Changes in Working Capital | -12.5268 | -18.2853 | -18.2824 | -14.7922 | -11.4582 |
| Cash From Investing Activities | -1.9446 | -13.9112 | -10.1627 | -6.78217 | -2.84209 |
| Capital Expenditures | -1.9446 | -13.9112 | -10.1627 | -6.78217 | -2.84209 |
| Other Investing Cash Flow Items, Total | |||||
| Cash From Financing Activities | -0.65051 | 108.852 | 46.1085 | 46.9523 | 47.2713 |
| Financing Cash Flow Items | -0.64095 | -7.68177 | -5.61423 | -4.77968 | -4.46973 |
| Issuance (Retirement) of Stock, Net | 64.8203 | 0 | 0 | 0 | |
| Issuance (Retirement) of Debt, Net | -0.00956 | 51.7133 | 51.7227 | 51.732 | 51.7411 |
| Net Change in Cash | -17.3174 | 35.4324 | -16.1831 | 1.32594 | 18.4158 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
Trade commission
0
- 1:1
Leverage
1:1
- 20
- 100
- 500
- 1000
- 10000
Investment
Trade size (Leverage x Investement):
Open
Close
Short Long
ADMA Biologics, Inc. Company profile
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.| Industry: | Biopharmaceuticals |
C/O Adma Biologics, Inc.
465 State Route 17
RAMSEY
NEW JERSEY 07446
US
Income Statement
- Annual
- Quarterly
News
US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024
Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024
US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024
How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024
A way forward: a roundup of recent central bank decisions
Five of the world’s most significant central banks delivered policy this week. We review the decisions and discuss their impact on the markets.
12:47, 22 March 2024
Bank of Japan Preview: will the BOJ end negative interest rates?
The Bank of Japan meets on Tuesday 19th of March. We preview what to expect from the BOJ decision and how it might impact the USD/JPY and Nikkei 225.
08:44, 18 March 2024
Higher CPI leaves traders unfazed as US equities continue to build momentum
The latest US CPI reading hasn’t gone how the Federal would have hoped. Consumer prices came in higher than expected in February for the third month in a row.
12:42, 15 March 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com